恩替卡韦联合自制乙肝2号治疗慢性乙型肝炎的临床观察

Clinical observation of entecavir combined with self-made hepatitis B 2 in the treatment of chronic hepatitis B

目的观察恩替卡韦胶囊联合自制乙肝2号溶液治疗慢性乙型肝炎的临床疗效。方法选择2015年10月~2016年10月经临床和实验室检查确诊的100例慢性乙型肝炎患者,采用随机数字表分为两组,对照组50例在常规治疗基础上加用恩替卡韦胶囊治疗,观察组在对照组基础上给予口服自制乙肝2号溶液,两组疗程均为1年,对比观察两组肝功能、肝纤维化指标和超声影像学指标、HBeAg阴转率等情况。结果治疗前两组的肝功能(ALT、AST、TBil、ALB)比较差异无统计学意义(P>0.05),治疗后,两组的TBil、ALT、AST、ALB均较治疗前显著改善(P<0.05),观察组的ALT、TBil较对照组改善更明显(P<0.05)。治疗前两组的肝纤维化指标(HA、LN、Ⅳ-C、PC-Ⅲ)比较差异无统计学意义(P>0.05),治疗后,两组的HA、LN、Ⅳ-C、PC-Ⅲ均较治疗前显著改善(P<0.05),观察组较对照组改善更明显(P<0.05)。观察组HBeAg转阴率为34.0%,对照组HBeAg转阴率为16.0%,两组比较差异有统计学意义(P<0.05),两组HBV-DNA转阴率比较差异无统计学意义(P>0.05)。结论恩替卡韦联合自制乙肝2号治疗慢性乙型肝炎,能够显著改善患者的肝功能,减轻肝纤维化程度,有效提高HBeAg转阴率,值得临床应用和进一步研究。

Objective To observe the clinical efficacy of entecavir capsule combined with self-made hepatitis B 2 in the treatment of chronic hepatitis B.Methods 100 patients who were diagnosed with chronic hepatitis B by clinical and laboratoty examination from October,2015 to October,2016 were selected and divided into two groups by random number table.The control group （n = 50） were treated with entecavir capsules on the basis of conventional treatment,and the observation group were given oral self-made hepatitis B 2 solution on the basis of the control group.The two groups were treated for 1 year.And then, liver tunction, liver fibrosis index, ultrasound imaging index, HBeAg negative conversion rate were compared between the two groups.Results There was no statistically significant ditterence in liver tunction（ ALT, AST, TBil and ALB） between the two groups betore treatment（P〉0.05）.Alter treatment,the TBil, ALT, AST and ALB of the two groups significantly improved while comparing with those betore treatment（P〈0.05 ）.ALT and TBil of the observation group improved more significantly than those of the control group（P〈0.05） .Ditterence of the liver fibrosis indexes（ HA,LN, IV-C and PC-Ⅲ ） in the two groups was not statistically significant before treatment（ P〉0.05 ） .Alter treatment, the HA, LN, IV-C and PC-Ⅲ of the two groups sig-nificantly improved（ P〈0.05 ） , and those of the observation group improved more significantly than those of the control group （P〈0.05）.HBeAg negative conversion rate of the observation group was 34.0%, and that of the control group was 16.0%, difference was statistically significant（ P〈0.05 ）.There was no statistically significant difference in HBV-DNA conversion rate between the two groups （P〉0.05）.Conclusion Entecavir combined with self-made hepatitis B 2 in the treatment of chronic hepatitis B can significantly improve liver tunction, reduce the degree of liver fibrosis, and ettectively improve the negative conversion rate of HBeAg,which is worthy of clinical application and further study.